1. Is Pfizer’s established drugs’ decline in China a canary in a coalmine? — Amgen biosimilar debut boosted by UnitedHealthcare coverage — Novartis CEO says FDA process could’ve been handled better — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. What happened a year ago this week in biopharma? Regeneron’s Eylea approval, Novartis’ new ethics czar, Vertex’s Kalydeco, and Opidvo’s SCLC approval click to review and read a current update of the big stories from one year ago
    Dismiss Notice

Shiel

Discussion in 'Shiel' started by Anonymous, Aug 15, 2013 at 7:01 PM.

Thread Status:
Not open for further replies.
  1. anonymous

    anonymous Guest


    Are you crazy? Not even a nugget was found.

    But if it does occur, two selfish ,money hungry pricks who deserve whatever they get
     
  2. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    11,595
    Likes Received:
    3
    This thread is being locked to further posts, as it has become too long. To enhance discussion about different topics at the company, please create new threads on the Shiel board (separate threads for different subjects), rather than a single thread for all posts.
     

Thread Status:
Not open for further replies.